Table 5.
Site-specific tumor incidence with SIRs (N = 5933; 35 667 person-years)
| Tumor site | Reported SN cases, n (%) or n | SIR (95% CI)* | P |
|---|---|---|---|
| Head and neck | 18 (25) | ||
| Tongue | 5 | 490 (159 to >1000) | <.001 |
| Mouth | 2 | 113 (14-408) | <.001 |
| Oropharynx | 2 | >1000 (309 to >1000) | <.0001 |
| Hypopharynx | 1 | >1000 (32 to >1000) | .002 |
| Nose, sinuses | 1 | 47 (1.2-264) | .042 |
| Oropharynx, unspecified | 7 | — | — |
| Hematologic | 19 (27) | ||
| Lymphoid leukemia | 3 | 3 (0.65-9) | .143 |
| Myeloid leukemia | 8 | 23 (9.7-44) | <.001 |
| MDS | 7 | 730 (293 to >1000) | <.001 |
| MDS, unspecified | 1 | — | — |
| Skin | 9 (13) | ||
| Melanoma of the skin | 2 | 7 (0.8-25) | .071 |
| Nonmelanoma skin | 7 | 68 (27-140) | <.001 |
| Bone and soft tissue | 7 (10) | ||
| Connective, soft tissue | 2 | 6 (0.8-23) | .083 |
| Bone | 2 | 6 (0.7-21) | .096 |
| Sarcoma, unspecified | 3 | — | — |
| Thyroid | 5 (7) | 16 (5.2-37) | <.001 |
| GI/GU | 7 (10) | ||
| Liver | 2 | 28 (3-100) | .005 |
| Cervix uteri | 1 | 13 (0.3-74) | .145 |
| Testis | 1 | 3 (0.1-15) | .607 |
| Bladder | 1 | 42 (1.0-234) | .047 |
| GI/GU, unspecified | 2 | — | — |
| Brain, CNS | 2 (3) | 2 (0.3-8) | .473 |
| Breast | 1 (1) | 10 (0.3-58) | .184 |
| Other, unspecified | 3 (4) | — | — |
CNS, central nervous system; GI, gastrointestinal; GU, genitourinary.
*
Based on number of SN cases with assigned ICD-10 codes (n = 55).